--- title: "Alto Neuroscience | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295706918.md" datetime: "2026-08-12T20:36:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295706918.md) - [en](https://longbridge.com/en/news/295706918.md) - [zh-HK](https://longbridge.com/zh-HK/news/295706918.md) generator: "portal-rs" --- # Alto Neuroscience | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.65, beating the estimate of USD -0.7346. EBIT: As of FY2026 Q2, the actual value is USD -27.15 M. Alto Neuroscience, Inc. reported its financial results for the fiscal quarter ended June 30, 2026. #### Cash Position As of June 30, 2026, cash, cash equivalents, and restricted cash totaled $244.2 million, an increase from $177.0 million as of December 31, 2025. Giving effect to the net proceeds from the July 2026 offering, the pro forma cash position was approximately $338 million. #### Operating Expenses (Three Months Ended June 30) Research and development expenses increased to $22,108 thousand in 2026 from $13,124 thousand in 2025. General and administrative expenses rose to $7,021 thousand in 2026 from $5,558 thousand in 2025. Total operating expenses were $29,129 thousand in 2026, compared to $18,682 thousand in 2025. #### Operating Expenses (Six Months Ended June 30) Research and development expenses increased to $42,402 thousand in 2026 from $23,098 thousand in 2025. General and administrative expenses increased to $13,865 thousand in 2026 from $11,260 thousand in 2025. Total operating expenses were $56,267 thousand in 2026, compared to $34,358 thousand in 2025. #### Loss from Operations Loss from operations for the three months ended June 30, 2026, was -$29,129 thousand, compared to -$18,682 thousand for the same period in 2025. For the six months ended June 30, 2026, loss from operations was -$56,267 thousand, compared to -$34,358 thousand for the same period in 2025. #### Net Loss Net loss for the three months ended June 30, 2026, was -$27,638 thousand, compared to -$17,706 thousand for the same period in 2025. For the six months ended June 30, 2026, net loss was -$53,875 thousand, compared to -$32,875 thousand for the same period in 2025. #### Other Income (Expense) (Three Months Ended June 30) Interest income was $2,112 thousand in 2026, up from $1,683 thousand in 2025. Interest expense was -$491 thousand in 2026, an improvement from -$646 thousand in 2025. Other, net, was -$130 thousand in 2026, compared to -$61 thousand in 2025. Total other income, net, was $1,491 thousand in 2026, up from $976 thousand in 2025. #### Other Income (Expense) (Six Months Ended June 30) Interest income was $3,673 thousand in 2026, up from $3,510 thousand in 2025. Interest expense was -$1,036 thousand in 2026, an improvement from -$1,244 thousand in 2025. Loss on debt extinguishment was -$0 thousand in 2026, compared to -$681 thousand in 2025. Other, net, was -$245 thousand in 2026, compared to -$102 thousand in 2025. Total other income, net, was $2,392 thousand in 2026, up from $1,483 thousand in 2025. #### Balance Sheet Data Total assets were $254,066 thousand as of June 30, 2026, compared to $184,689 thousand as of December 31, 2025. Total liabilities were $34,817 thousand as of June 30, 2026, compared to $33,547 thousand as of December 31, 2025. Accumulated deficit was -$255,509 thousand as of June 30, 2026, compared to -$201,634 thousand as of December 31, 2025. #### Financing In July 2026, Alto Neuroscience, Inc. completed an underwritten registered direct offering, generating gross proceeds of approximately $100.0 million and net proceeds of approximately $94.6 million. #### Outlook / Guidance Alto Neuroscience, Inc. anticipates its pro forma cash position of approximately $338 million will fund planned operations through 2030. Key upcoming milestones include the initiation of the ALTO-207 PACE-2 and PACE-3 trials in early and second half of 2027, respectively. Topline data for the ALTO-300 Phase 2b MDD trial is expected in the first half of 2027, for ALTO-100 Phase 2b BPD trial in mid-2027, and for ALTO-207 PACE-1 trial in the second half of 2027. ### Related Stocks - [ANRO.US](https://longbridge.com/en/quote/ANRO.US.md) ## Related News & Research - [ANRO: Precision psychiatry pipeline advances with biomarker-driven therapies and strong clinical data](https://longbridge.com/en/news/295708046.md) - [Alto Neuroscience posts corporate presentation outlining precision psychiatry drug pipeline, led by ALTO-207 in treatment-resistant depression](https://longbridge.com/en/news/295705980.md) - [Alto Neuroscience Raises Capital to Advance ALTO-207](https://longbridge.com/en/news/292732821.md) - [Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials](https://longbridge.com/en/news/292491782.md) - [Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat](https://longbridge.com/en/news/295819442.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**